Research
Hormonal
Holding one dose of GLP-1 or GIP agonists significantly reduces the risk of clinically significant RGV.
Holding the medication prior to the procedure is advisable to minimize RGV risk.
StrongSupportsmedium confidence
Clinically significant RGV occurred in 3.1% in the hold group vs 25.0% in the continue group.
Why this rating
Based on a randomized clinical trial design.
Source
Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy
Akram I. Ahmad et al. · JAMA Internal Medicine · 2026
DOI 10.1001/jamainternmed.2026.0027
rct · n=60Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →